An arsenic oxide in which arsenic and oxygen atoms are present in the ratio 2:3.
Chemical ID:
MESH:C006632
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
18alpha,20beta-hydroxy-11-oxo-norolean-12-en-3beta-yl-2-O-beta-D-glucopyranurosyl-alpha-D-glucopyranosiduronate magnesium tetrahydrate inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; [Genistein co-treated with Arsenic Trioxide] results in decreased expression of BCL2 protein; Arsenic Trioxide promotes the reaction [Drugs, Chinese Herbal results in decreased expression of BCL2 protein]; baicalin inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; Drugs, Chinese Herbal promotes the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; MIR34A affects the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; Propranolol inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]
Arsenic Trioxide results in decreased expression of BCL2; Arsenic Trioxide results in decreased expression of BCL2 mRNA; Arsenic Trioxide results in decreased expression of BCL2 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvianolic acid B inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]]; [alpha-Tocopherol co-treated with Ascorbic Acid] inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; ferrostatin-1 inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; HTS 466284 inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; Phloretin inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 mRNA]; pifithrin inhibits the reaction [Arsenic Trioxide results in increased expression of BCL2 mRNA]; salvianolic acid A inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; salvianolic acid B inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; Taurine inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; trans-sodium crocetinate inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of BCL2 protein]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Arsenic Trioxide affects the localization of BCL2 protein]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Arsenic Trioxide results in increased expression of BCL2 mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Arsenic Trioxide results in increased expression of BCL2 protein]; 3-methyladenine inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2]; 4-amino-1,8-naphthalimide inhibits the reaction [Arsenic Trioxide results in increased expression of BCL2 protein]; [Arsenic Trioxide co-treated with Aprepitant] results in decreased expression of BCL2 mRNA; [Arsenic Trioxide co-treated with Ascorbic Acid co-treated with Disulfiram] results in decreased expression of BCL2 protein; [Arsenic Trioxide co-treated with BCL2 mutant form] results in increased expression of BCL2 protein; [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of BCL2 mRNA; [Arsenic Trioxide co-treated with Curcumin] affects the expression of BCL2 protein; [Arsenic Trioxide co-treated with Doxorubicin co-treated with Magnetite Nanoparticles analog] affects the expression of BCL2 mRNA; [Arsenic Trioxide co-treated with Doxorubicin co-treated with Magnetite Nanoparticles analog] affects the expression of BCL2 protein; [Arsenic Trioxide co-treated with epigallocatechin gallate] results in decreased expression of BCL2 protein; [Arsenic Trioxide co-treated with NVP-BKM120] results in decreased expression of BCL2 mRNA; [Arsenic Trioxide co-treated with PML protein] results in decreased expression of BCL2; [Arsenic Trioxide results in increased phosphorylation of BCL2 protein] inhibits the reaction [BCL2 protein binds to BAX protein]; [BIBR 1532 co-treated with Arsenic Trioxide] affects the expression of BCL2 mRNA; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of BCL2 protein; [Bortezomib co-treated with Arsenic Trioxide] results in decreased expression of BCL2 protein; [Curcumin co-treated with Arsenic Trioxide] results in decreased expression of BCL2 protein; [Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of BCL2 mRNA; [Genistein co-treated with Arsenic Trioxide] results in decreased expression of BCL2 protein; [Hydrogen Peroxide co-treated with Arsenic Trioxide] results in decreased expression of BCL2 protein; [MARVELD1 protein results in decreased susceptibility to Arsenic Trioxide] which results in increased expression of BCL2 protein; [paricalcitol co-treated with Arsenic Trioxide] results in decreased expression of BCL2; [pifithrin co-treated with Arsenic Trioxide] results in decreased expression of BCL2 protein; [ruxolitinib co-treated with Arsenic Trioxide] results in decreased expression of BCL2 mRNA; [Silybin co-treated with Arsenic Trioxide] results in decreased expression of BCL2 mRNA; [tetraarsenic tetrasulfide co-treated with Arsenic Trioxide] results in decreased expression of BCL2 mRNA; [tetraarsenic tetrasulfide co-treated with Arsenic Trioxide] results in decreased expression of BCL2 protein; [Tretinoin co-treated with Arsenic Trioxide] results in decreased expression of BCL2 mRNA; [Valproic Acid co-treated with Arsenic Trioxide] results in decreased expression of BCL2 mRNA; [Valproic Acid co-treated with Arsenic Trioxide] results in decreased expression of BCL2 protein; [Vorinostat co-treated with Arsenic Trioxide] results in decreased expression of BCL2 protein; Acetylcysteine inhibits the reaction [Arsenic Trioxide promotes the reaction [Resveratrol results in decreased expression of BCL2 protein]]; Acetylcysteine inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; Acetylcysteine inhibits the reaction [Arsenic Trioxide results in increased expression of and affects the localization of BCL2 protein]; Acetylcysteine inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of BCL2 protein]; Acetylcysteine inhibits the reaction [Resveratrol promotes the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]]; Arsenic Trioxide inhibits the reaction [BCL2 protein binds to BAX protein binds to VDAC1 protein]; Arsenic Trioxide inhibits the reaction [BCL2 protein binds to BAX protein]; Arsenic Trioxide promotes the reaction [Genistein results in decreased expression of BCL2 protein]; Arsenic Trioxide promotes the reaction [Matrines results in decreased expression of BCL2 protein]; Arsenic Trioxide promotes the reaction [puerarin results in decreased expression of BCL2 mRNA]; Arsenic Trioxide promotes the reaction [Resveratrol results in decreased expression of BCL2 protein]; Arsenic Trioxide promotes the reaction [TGFB1 protein results in decreased expression of BCL2 protein]; Arsenic Trioxide results in decreased expression of and affects the localization of BCL2 protein; Arsenic Trioxide results in increased expression of and affects the localization of BCL2 protein; BCL2 inhibits the reaction [[Arsenic Trioxide co-treated with TNF protein] results in decreased expression of CFLAR protein]; BCL2 inhibits the reaction [[Arsenic Trioxide co-treated with TNF protein] results in increased activity of CASP8 protein]; BCL2 protein inhibits the reaction [[Arsenic Trioxide co-treated with lonidamine] results in increased cleavage of and results in increased activity of CASP8 protein]; BCL2 protein inhibits the reaction [[Arsenic Trioxide co-treated with Quercetin] results in increased cleavage of and results in increased activity of CASP8 protein]; BCL2 protein inhibits the reaction [Arsenic Trioxide inhibits the reaction [BCL2 protein binds to BAX protein]]; BCL2 protein inhibits the reaction [Arsenic Trioxide promotes the reaction [lonidamine results in increased cleavage of and results in increased activity of CASP9 protein]]; BCL2 protein inhibits the reaction [Arsenic Trioxide results in decreased expression of MYC mRNA]; BCL2 protein inhibits the reaction [Arsenic Trioxide results in increased activity of BAX protein]; BCL2 protein inhibits the reaction [Arsenic Trioxide results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [lonidamine promotes the reaction [Arsenic Trioxide results in increased cleavage of and results in increased activity of CASP9 protein]]; Cycloheximide inhibits the reaction [Arsenic Trioxide results in increased expression of BCL2 protein]; Dactinomycin inhibits the reaction [Arsenic Trioxide results in increased expression of BCL2 protein]; Dithiothreitol inhibits the reaction [Arsenic Trioxide results in increased expression of BCL2 protein]; Genistein promotes the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; GH1 protein promotes the reaction [Arsenic Trioxide results in decreased expression of BCL2 mRNA]; HOMER3 protein affects the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; ID1 protein inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; MAPK14 mutant form inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of BCL2 protein]; MAPK8 mutant form inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of BCL2 protein]; MAPK9 mutant form inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of BCL2 protein]; MARVELD1 protein inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; Matrines promotes the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; NVP-BKM120 promotes the reaction [Arsenic Trioxide results in decreased expression of BCL2 mRNA]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of BCL2 protein]; Resveratrol promotes the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; SB 203580 inhibits the reaction [Arsenic Trioxide affects the localization of BCL2 protein]; SB 203580 inhibits the reaction [Arsenic Trioxide results in increased expression of BCL2 mRNA]; SB 203580 inhibits the reaction [Arsenic Trioxide results in increased expression of BCL2 protein]; SB 203580 promotes the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; Wortmannin inhibits the reaction [[Hydrogen Peroxide co-treated with Arsenic Trioxide] results in decreased expression of BCL2 protein]
